Prostate Cancer

Robert B. Den, MD, outlines the exploratory applications of the Alpha DaRT technology across the prostate and bladder cancer landscapes.

Concurrent use of an ARPI with [177Lu]Lu-PSMA-617 did not improve response rates nor overall survival in patients with ARPI-refractory mCRPC.

According to the authors, these data support the value of PSMA PET/CT in the pre-salvage radiotherapy selection process.

The agent is currently being evaluated in a phase 1/2 trial.

Urologists from the University of North Carolina share insights into key advancements across the field of urologic oncology.

Timothy D. McClure outlines his approach to patient selection with focal therapy as well as how NanoKnife fits into that landscape.

The ArteraAI test is now the first and only AI-powered tool to be authorized to prognosticate long-term outcomes in patients with localized prostate cancer.

Panelists discuss how shared decision-making allows patients to test-drive oral androgen deprivation therapy options, providing flexibility for those concerned about quality-of-life impact or performance status, enabling them to start or stop treatment as needed.

Panelists discuss how patient preference plays a significant role in androgen deprivation therapy selection, with most patients preferring oral agents that offer rapid onset and quick testosterone recovery when treatment is stopped.

HIFU was shown to be an effective and tolerable treatment option for patients with intermediate-risk localized prostate cancer.

The target action date for the application is March 6, 2026.

Timothy D. McClure, MD, discusses focal therapy with IRE, specifically highlighting its benefits and limitations compared with other treatment options.

The phase 1 STRIKE-001 trial will evaluate KTX-2001 as both a monotherapy and in combination with darolutamide.

Data from the phase 2 EXTEND trial showed that the addition of metastasis-directed therapy to ADT improved measures of systemic disease control.

Take a look through key stories from last month, including regulatory news, trial updates, and other practice-changing advancements.

Panelists discuss how clinicians can confidently adapt to newer androgen deprivation therapy options like relugolix in combination therapies despite limited prospective data, emphasizing that oral agents simplify patient visits and provide equivalent testosterone suppression.

Panelists discuss how NCCN guidelines provide a framework for selecting appropriate androgen deprivation therapy (ADT) regimens across different disease states, with combination therapies now being standard of care rather than ADT monotherapy in most cases.

INKmune was well-tolerated across all 3 dose levels assessed.

Data showed that 1 in 6 men with GG1 prostate cancer ultimately had higher-risk disease when other clinical features were taken into account.

A recap of the FDA submissions and regulatory decisions in urology from July 2025.

ATNM-400 demonstrated improved efficacy compared with 177Lu-PSMA-617 in treatment-resistant models as well as enhanced efficacy in combination with enzalutamide.

Enzalutamide plus ADT was associated with significant improvements in rPFS and time to castration resistance compared with darolutamide plus ADT.

Panelists discuss how patient adherence to oral androgen deprivation therapy has been reliable in both clinical trials and practice, with the convenience of daily pills and portability during travel contributing to good compliance rates.

Panelists discuss how multiple pharmacologic and clinical factors influence androgen deprivation therapy selection, including mechanism of action, delivery method, patient preferences, cardiovascular risk profile, and the potential for rapid testosterone recovery.

The 500 mg regimen of abiraterone acetate demonstrated comparable anti-tumor activity and a favorable safety profile compared with the standard 1000 mg dose.